Online inquiry

IVTScrip™ mRNA-Anti-CD37, TRU-016(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ15386MR)

This product GTTS-WQ15386MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets CD37 gene. The antibody can be applied in Chronic lymphocytic leukemia (CLL), Non-Hodgkin's lymphoma (NHL) research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_001040031.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 951
UniProt ID P11049
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD37, TRU-016(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) (GTTS-WQ15386MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ4135MR IVTScrip™ mRNA-Anti-ICAM1, BI-505(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA BI-505
GTTS-WQ14588MR IVTScrip™ mRNA-Anti-CD38, SAR-650984(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA SAR-650984
GTTS-WQ1741MR IVTScrip™ mRNA-Anti-IL2RA, ADCT-301(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA ADCT-301
GTTS-WQ12039MR IVTScrip™ mRNA-Anti-NRP1, MNRP1685A(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA MNRP1685A
GTTS-WQ13496MR IVTScrip™ mRNA-Anti-IgG-Fc, PRTX-100(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA PRTX-100
GTTS-WQ9642MR IVTScrip™ mRNA-Anti-CD3E&TNFRSF17, JNJ-64007957(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA JNJ-64007957
GTTS-WQ10729MR IVTScrip™ mRNA-Anti-FCGRT, M-281(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA M-281
GTTS-WQ996MR IVTScrip™ mRNA-Anti-SLAMF7, ABBV-383(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA ABBV-383
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW